Few medtechs go public, but those that do, do nicely
Most medtechs that listed this year priced their IPOs at a premium, and most saw their shares appreciate.
Venture investing dips again for biopharma
The second quarter saw start-ups raise the smallest venture capital haul in two years, as the number of mega rounds declined.
Medtech VC and the billion-dollar era
The first one-shot billion-dollar venture investment round in the medical technology sector has gone to Verily as computing bleeds into medicine.
Biopharma set for a big buyout year – on dollar terms at least
The second mega-merger in as many quarters means a huge M&A year is in the making, but a look at deal volume tells another story.
Big device deals are back in fashion
The medtech market’s fast growth and unfettered demand attracts investment groups, while hospital suppliers consolidate.
Cannabis, M&A and data spur strong gains among small and midcaps
The usual story of positive data and clinical failure influencing company stock performance was given added interest in the second quarter with price fixing allegations…
Mid cap device makers find rewards in cancer and diabetes
Investor excitement about smaller medtechs’ technology is unchecked, but these groups will have to deliver on their promises.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.